InnoCare Pharma gets green light for Phase II trial of oral lupus drug
CLE, a common form of lupus erythematosus, primarily causes diverse skin lesions
CLE, a common form of lupus erythematosus, primarily causes diverse skin lesions
The new single-use commercial facility will be among India’s largest, featuring advanced technologies to produce high-quality biologics and specialty pharmaceuticals
If approved, imlifidase has the potential to transform the kidney transplant landscape by enabling highly sensitized patients to also have access to a potentially life-changing kidney transplant
The Phase 1 study will evaluate the safety, tolerability, and pharmacokinetics (PK) of ENV-6946 in healthy volunteers
NUFYMCO BLA has been approved by the USFDA
The MAR-Autism Test represents more than 20 years of research at the UC Davis MIND Institute by Judy Van de Water
Under the agreement, AVT06 is licensed to enter the US market in the fourth quarter of 2026
The seminar aimed to raise public awareness about inflammageing—chronic, low-grade inflammation that silently damages the body and accelerates ageing
The approval for Exdensur (depemokimab-ulaa) comes on the back of SWIFT-1 and SWIFT-2 Phase III trials
Subscribe To Our Newsletter & Stay Updated